NCT05744063 - A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

February 21, 2025

Study Completion Date

August 8, 2025

Conditions

Primary Hemophagocytic Lymphohistiocytosis

Interventions

DRUG

Emapalumab-Lzsg 5 MG/ML [Gamifant]

Trial Locations (7)

Swedish Orphan Biovitrum Research site, Shanghai

Swedish Orphan Biovitrum Research site, Beijing

Swedish Orphan Biovitrum Research site, Chongqing

Swedish Orphan Biovitrum Research site, Guangzhou

Swedish Orphan Biovitrum Research site, Nanjing

Swedish Orphan Biovitrum Research site, Zhengzhou